VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

FMDV DNA Vaccine encoding P1 and non-structural proteins 2A, 3C, and 3D
Vaccine Information
  • Vaccine Name: FMDV DNA Vaccine encoding P1 and non-structural proteins 2A, 3C, and 3D
  • Target Pathogen: Foot-and-mouth disease virus
  • Target Disease: Foot-and-mouth disease
  • Vaccine Ontology ID: VO_0004553
  • Type: DNA vaccine
  • Status: Research
  • P1 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • 2A gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • 3C gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • 3D gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cattle Response

  • Vaccination Protocol: Thirty-two cattle of 6–7 months of age were housed separately in six groups of five (vaccinated animals) and one group of two (un-vaccinated controls) within the isolation units at the Institute for Animal Health, Pirbright. The six groups of vaccinates were immunised as follows: Group 1 with 2 mg PLG-pcDNA3.1/P12A3C3D + 0.4 mg pcDNA3.1/bGM-CSF (DNA + PLG + GMCSF), Group 2 with 2 mg PLG-pcDNA3.1/P12A3C3D + 0.4 mg pcDNA3.1/bGM-CSF + electroporation (DNA + PLG + GMCSF + elec), Group 3 with 2 mg pcDNA3.1/P12A3C3D + 0.4 mg pcDNA3.1/bGM-CSF (DNA + GMCSF), Group 4 with 2 mg pcDNA3.1/P12A3C3D + 0.4 mg pcDNA3.1/bGM-CSF + electroporation (DNA + GMCSF + elec), Group 5 with 2 mg pcDNA3.1/P12A3C3D + electroporation (DNA + elec), and Group 6 with conventional vaccine (Fowler et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: All DNA vaccinated cattle generated a detectable neutralising antibody response at 21 days post 1st vaccination (Fowler et al., 2012).
  • Challenge Protocol: On day 133 post primary vaccination, four cattle in each of vaccination groups 3–6 only were randomly selected, together with two un-vaccinated controls and intradermolingually challenged in two sites with 105 TCID50, 0.1 ml per site, of cattle adapted O1 Lausanne FMDV (Fowler et al., 2012).
  • Efficacy: Conventionally vaccinated cattle were fully protected from experimental challenge, as determined by absence of generalised disease (Table 2). In addition 6 of the 8 DNA vaccinated cattle in groups 4 and 5 (DNA + GMCSF + elec and DNA + elec) were fully protected despite these DNA vaccinated animals being challenged 91 days after the protein boost (Fowler et al., 2012).
References